Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06693011 · ClinicalTrials.gov registry record · NA
Contour Neurovascular System™ ContiNued Access Investigational Device EXempTion (IDE) Trial (NEXT Trial)
A NA study of Cerebral Aneurysms, sponsored by Cerus Endovascular.
- Recruiting
- Registry status
- NA
- Development phase
- 250
- Enrollment target
- 4
- Study locations
NCT06693011: Recruiting NA study of Cerebral Aneurysms, sponsored by Cerus Endovascular.
NCT06693011 is a NA study of Cerebral Aneurysms that is actively recruiting participants, run by Cerus Endovascular. The registered enrollment target is 250 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (82% lower). The trial reports 4 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06693011, a NA study of Cerebral Aneurysms, is actively recruiting participants, sponsored by Cerus Endovascular.
- RECRUITING
- Registry status
- NA
- Development phase
- 250 participants
- Enrollment target
- 4
- Study locations
Study Summary
The goal of this clinical trial is to collect additional data to demonstrate if the Contour Neurovascular System (CNS) is a safe and effective treatment of wide-necked, saccular, intracranial aneurysms. Participants will: Undergo treatment with the Contour Neurovascular System Complete follow-up visits at 1month, 12months, and 24 months, following their procedure Report any adverse events to their study team
Primary Outcome
Death or stroke within 30 days of treatment or ipsilateral stroke or neurological death between 30 days and 1 year. Stroke is defined per the World Health Organization as: rapidly developing clinical signs of focal or global disturbance of cerebral function lasting more than 24 hours with no apparent cause other than of vascular origin, including ischemic stroke and/or hemorrhagic stroke.
Conditions Studied
Interventions
- DEVICE Contour Neurovascular System Treatment Attempt
Study Locations (4)
New York
- University at Buffalo Neurosurgery - Buffalo
- Stony Brook University - Stony Brook
Pennsylvania
- University of Pennsylvania - Philadelphia
Washington
- Swedish Neuroscience Institute - Seattle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 250 participants |
| Start Date | 2025-06-10 |
| Est. Completion | 2030-01 |
| Phase | NA |
What NCT06693011 shows while recruiting
NCT06693011 is an interventional study that assigns participants to a tested intervention. The registered 250 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (82% lower).
The record links to 1 condition, with Cerebral Aneurysms appearing as the primary indexed condition, and to 1 intervention - of which Contour Neurovascular System Treatment Attempt is the first listed.
NCT06693011 reports a single indexed study location in New York, Pennsylvania, Washington.
Frequently Asked Questions
What is clinical trial NCT06693011 about?
NCT06693011 is a clinical study titled "Contour Neurovascular System™ ContiNued Access Investigational Device EXempTion (IDE) Trial (NEXT Trial)". The goal of this clinical trial is to collect additional data to demonstrate if the Contour Neurovascular System (CNS) is a safe and effective treatment of wide-necked, saccular, intracranial aneurysms. Participants will: Undergo treatment with the Contour Neurovascular System Complete follow-up v...
What is the current status of trial NCT06693011?
This trial is currently recruiting. It is a NA study. The enrollment target is 250 participants. The study started on 2025-06-10. Estimated completion is 2030-01.
What conditions does trial NCT06693011 study?
This clinical trial studies the following conditions: Cerebral Aneurysms.
What interventions are being tested in trial NCT06693011?
The interventions under investigation include: Contour Neurovascular System Treatment Attempt (DEVICE).
Who is sponsoring clinical trial NCT06693011?
This trial is sponsored by Cerus Endovascular, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06693011 being conducted?
This trial has 4 study locations across New York, Pennsylvania, Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cerebral Aneurysms
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06693011's enrollment target sits among peer trials
250 410th of 2000 higher than 1,567 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00483249 · 250 participants · NA
Endovascular Exclusion of Thoracoabdominal and/or Paravisceral Abdominal Aortic Aneurysm
- NCT00777712 · 250 participants
Mechanisms Underlying Impaired Diabetic Wound Healing
- NCT01451502 · 250 participants · NA
Infusion of Cell Populations From Unlicensed Umbilical Cord Blood Units
- NCT01771718 · 250 participants
Pilot Study on In-vivo Non-invasive Skin Imaging Using Multiphoton Microscopy
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI